ArticleApplied health economics and health policy2022

Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.

Nidhi Gupta et al.PubMed ↗Publisher ↗

No numbers read from the abstract.